source
- City Therapeutics raises $200M in IPO to fund thromboembolic disease pipelineCity Therapeutics, an RNA interference biotech focused on thromboembolic diseases, completed an initial public offering that raised $200 million. The company sold about 11 million shares at $18 ea…
- Estuary sails into kidney disease space with $103M for gene therapiesEstuary Biotherapeutics is seeking to address the root cause of autosomal dominant polycystic kidney disease with two gene therapy programs based on science from Yale.BioSpace · 3d ago↗ source